The company has quietly emerged as the key player to watch in an area that has seen several setbacks of late.
The German group’s decision to switch focus to innate immunity had been on the cards since a deal with Roche last August.
The mere possibility of Guardant horning in on colorectal cancer has spooked Exact’s investors.
The companies’ decision to start a 1,500-patient Alzheimer’s disease study defies logic.
Probiodrug grabs $15m, but it will need more to fund phase IIb development of its Alzheimer’s candidate, PQ912.
Scholar Rock selects a lead molecule inhibiting TGF-β, an increasingly important oncology mechanism that Glaxosmithkline recently paid €300m to enter.
Eidos presses ahead in its David and Goliath battle against Pfizer in amyloidosis, but it could have issues with pivotal trial recruitment.
The first sickle cell and beta thalassaemia patients have been enrolled into a Crispr/Cas9 trial, heating up a race with Bluebird, Sanofi, Sangamo and Editas.
The French company has taken a look at its R&D portfolio, and made some radical changes in oncology and diabetes.